Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
30.3M
-
Number of holders
-
163
-
Total 13F shares, excl. options
-
34.9M
-
Shares change
-
+3.32M
-
Total reported value, excl. options
-
$2.03B
-
Value change
-
+$197M
-
Put/Call ratio
-
0.12
-
Number of buys
-
92
-
Number of sells
-
-61
-
Price
-
$58.07
Significant Holders of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) as of Q3 2024
186 filings reported holding KROS - Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q3 2024.
Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) has 163 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34.9M shares
.
Largest 10 shareholders include FMR LLC (4.9M shares), BlackRock, Inc. (2.63M shares), ALKEON CAPITAL MANAGEMENT LLC (1.9M shares), VANGUARD GROUP INC (1.86M shares), Darwin Global Management, Ltd. (1.52M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.51M shares), STATE STREET CORP (1.11M shares), ORBIMED ADVISORS LLC (1.02M shares), Point72 Asset Management, L.P. (948K shares), and TCG Crossover Management, LLC (879K shares).
This table shows the top 163 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.